ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Mar 2018
Last Updated on 18 Jan 2021
A- A+
Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn’s disease Guidance is outdated and has been withdrawn on 18 Jan 2021.
Please refer to the updated recommendations on Infliximab biosimilar for treating inflammatory conditions here. Infliximab for the treatment of RA AS PsA Plaque Psoriasis UC Crohn's disease (Withdrawn 18 Jan 2021)